Please ensure Javascript is enabled for purposes of website accessibility

Why Denali Therapeutics Stock Is Soaring Today

By Brian Feroldi - Jan 14, 2020 at 3:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jump after the company releases upbeat clinical news.

What happened

Shares of Denali Therapeutics (DNLI 2.45%), a biopharmaceutical company focused on neurodegenerative diseases, rose 24% as of 2:36 p.m. EST on Tuesday in response to announcing that its pipeline is progressing.

So what

Here are the key takeaways for investors:

  • DNL201 showed "high levels of target and pathway engagement and improvement of lysosomal biomarkers" in a phase 1b trial testing the compound as a hopeful treatment for Parkinson's disease. The drug also met all of the trial's biomarker goals and was generally well tolerated at the low dose. The majority of subjects experienced either mild or moderate adverse events at the high dose, however.
  • DNL151 showed "high levels of target and pathway engagement and modulation of lysosomal biomarkers in healthy volunteers" in a Phase 1b study in patients with Parkinson's disease. The trial also met all safety and biomarker goals and DNL151 was generally safe and well-tolerated at all doses tested.
  • An IND has been submitted for DNL310, a hopeful treatment for Hunter syndrome. A phase 1/2 trial will be initiated if Denali receives clearance. 
  • DNL747 phase 1b trial in Alzheimer's disease and amyotrophic lateral sclerosis (ALS, which is more commonly known as Lou Gehrig's disease) is fully enrolled. Data is expected by the middle of 2020.
  • A clinical trial application (CTA) has been approved for a Phase 1 study of DNL343 as a hopeful treatment for ALS and other neurodegenerative diseases.
Group of researchers pointing at DNA

Image source: Getty Images.

Given the deluge of upbeat clinical news, it's easy to understand why shares are flying high today. 

Now what

Denali's CEO Ryan Watts stated: "We are also enthusiastic about advancing two new molecules toward the clinic, DNL343 for ALS and other neurodegenerative diseases and DNL310 for Hunter syndrome, which is also expected to generate proof-of-concept in humans for our Transport Vehicle blood-brain barrier delivery platform."

Neurodegenerative diseases like Alzheimer's and ALS are notoriously difficult to treat, so it's highly encouraging to see that Denali continues to make clinical progress. However, history shows that even the most promising biotechnology drugs often fail in late-stage trials, so investors shouldn't get their hopes up just yet. That's why my plan is to root for Denali's success from the safety of the sidelines. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Denali Therapeutics Inc. Stock Quote
Denali Therapeutics Inc.
$30.93 (2.45%) $0.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.